Bipolar Androgen Therapy
Bipolar Androgen Therapy (BAT) is an investigational treatment approach developed primarily for men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed despite standard androgen deprivation therapy (ADT) and often after androgen receptor pathway inhibitors (like abiraterone or enzalutamide). It is not a standard or FDA-approved therapy for prostate cancer (or any other cancer) but has been studied in multiple clinical trials, with promising results in a subset of patients.
It is not used or studied for other types of cancer—all available evidence is specific to prostate cancer due to its dependence on androgen signaling.
How BAT Works
Prostate cancer cells typically rely on androgens (like testosterone) to grow. Standard ADT lowers testosterone to castrate levels (<50 ng/dL), which initially shrinks tumors, but over time many cancers adapt by upregulating androgen receptors (AR). These resistant cells thrive in a low-testosterone environment.
BAT creates rapid "hormone shocks" by cycling between:
- Supraphysiologic (very high) testosterone levels (often >1,000 ng/dL)
- Castrate (very low) levels (maintained via ongoing ADT)
This prevents adaptation. High-dose testosterone overloads the upregulated ARs, disrupting cell division, inducing DNA damage, inhibiting growth genes, and sometimes triggering cell death or immune responses. The rapid swings (high → low every ~28 days) keep the cancer cells off-balance.

sciencedirect.com
The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy – ScienceDirect
(Visual: High-dose androgen overwhelms AR signaling, leading to DNA breaks, decreased AR expression, cell cycle arrest, and tumor growth inhibition.)
How BAT Is Administered
Patients continue standard ADT (injections or surgery to suppress natural testosterone) and receive 400 mg intramuscular testosterone cypionate (a generic, FDA-approved form of testosterone) injected into the buttock muscle every 28 days. This creates the "bipolar" cycle as levels peak high and then drop back to castrate. Treatment is typically given in cycles and monitored with PSA tests, scans, and clinical exams. It is usually reserved for asymptomatic or minimally symptomatic patients.
Evidence and Results from Key Studies
Multiple phase 2 trials (led by researchers like Samuel Denmeade, MD, at Johns Hopkins) have evaluated BAT:
- Response rates: PSA50 (≥50% drop in PSA) responses in ~27–40% of patients; objective response rates (tumor shrinkage on scans) ~24–34%.
- Resensitization: BAT often restores sensitivity to subsequent anti-androgen drugs (e.g., enzalutamide or abiraterone), with PSA50 responses up to ~57–80% on rechallenge in some sequencing studies.
- Key trials:
- TRANSFORMER: BAT performed similarly to enzalutamide alone (PSA responses ~25%, ~6 months duration) but sequencing BAT before enzalutamide improved outcomes significantly.
- COMBAT (BAT + nivolumab immunotherapy): Confirmed PSA50 response rate of 40%; median radiographic progression-free survival ~5.6 months, overall survival ~24 months.
- Other trials (e.g., RESTORE, BATMAN, ExBAT): Consistent safety and activity, with some durable responses (>12 months) in ~30–40% of patients.
Ongoing trials are exploring BAT earlier (e.g., non-metastatic CRPC), in combinations (immunotherapy, other drugs), and optimized sequencing.
Benefits and Quality of Life
In responders, BAT often:
- Improves energy, physical function, muscle mass, and reduces fatigue.
- Restores sexual function and libido (many men regain erections).
- Counters some ADT side effects (e.g., less abdominal fat, better cholesterol profiles).
This makes it appealing for men who have been on long-term ADT and are experiencing its debilitating effects.
Safety and Side Effects
BAT is generally well-tolerated in properly selected (asymptomatic) patients. Most side effects are mild-moderate:
- Hot flashes, breast tenderness/enlargement, muscle aches, leg swelling.
- Temporary pain flare possible in men with symptomatic bone metastases (not recommended for those with significant pain).
- Rare serious risks: cardiovascular events (e.g., in those with heart failure), hypertension, or fluid retention.
Grade 3+ adverse events are low (~9–14%). It is not suitable for hormone-sensitive prostate cancer or patients with symptomatic disease.
Current Status and Practical Advice
BAT remains experimental and is best accessed through clinical trials (search clinicaltrials.gov for “bipolar androgen therapy” or “BAT prostate”). Some centers offer it off-label, but insurance coverage can be an issue since it is not FDA-approved for this indication. Testosterone itself is inexpensive and widely available, but proper monitoring is essential.
Important: This is not medical advice. BAT is not a cure and does not work for everyone (~60–70% may not respond). Discuss with a prostate cancer specialist (urologist or medical oncologist) to see if you are a candidate, especially if you have progressed on standard therapies. They can review your case, biomarkers (e.g., AR status or DNA changes may help predict response), and trial options near you.
For the latest, refer to sources like the Prostate Cancer Foundation, Johns Hopkins, or recent ASCO presentations. Research is active, with larger phase 3 trials potentially on the horizon to establish its role in standard care.
Popular Handouts
- Testosterone Anastrozole In Breast Cancer Survivors
- Breast Cancer Response To Testosterone Anastrozole Implants
- MALE DATA Testosterone Anastrozole Therapy In Men
- Testosterone Pellet Implants And Migraine Headaches A Pilot Study
- Breast Cancer In The Elderly
- Testosterone And Chemotherapy
- Reduced Incidence Of Breast Cancer With Testosterone Implant Therapy 10 Year Results
- Beneficial Effects Of Testosterone Therapy In Women
- Testosterone And Breast Cancer Prevention
- Low Testosterone Levels In Breast Cancer Patients
- Testosterone Dosing And Levels In Women
- Testosterone Anastrozole And Venous Thrombosis
- The Top 10 Myths And Misconceptions About Testosterone In Women